Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
Condition(s):Acute Myeloid LeukemiaLast Updated:May 20, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Acute Myeloid LeukemiaLast Updated:May 20, 2020Completed
Condition(s):Acute Promyelocytic LeukemiaLast Updated:August 19, 2019Unknown status
Condition(s):LeukemiaLast Updated:October 26, 2022Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:January 30, 2024Recruiting
Condition(s):LymphomaLast Updated:September 17, 2013Unknown status
Condition(s):Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Last Updated:February 8, 2024Active, not recruiting
Condition(s):Acute Myeloid LeukemiaLast Updated:July 21, 2022Completed
Condition(s):LeukemiaLast Updated:July 27, 2023Active, not recruiting
Condition(s):MDSLast Updated:February 19, 2019Unknown status
Condition(s):LeukemiaLast Updated:February 22, 2024Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.